JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martínez, V.
Right arrow Articles by Taché, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez, V.
Right arrow Articles by Taché, Y.

Vol. 290, Issue 2, 629-634, August 1999

Peripheral Injection of a New Corticotropin-Releasing Factor (CRF) Antagonist, Astressin, Blocks Peripheral CRF- and Abdominal Surgery-Induced Delayed Gastric Emptying in Rats1

Vicente Martínez2, Jean Rivier and Y. Taché

CURE: Digestive Diseases Research Center, West Los Angeles Veterans Administration Medical Center, Department of Medicine, Digestive Disease Division, and Brain Research Institute, University of California at Los Angeles School of Medicine, Los Angeles, California; and The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, California (J.R.)

The effect of the corticotropin-releasing factor (CRF) receptor antagonists astressin and D-Phe CRF12-41 injected i.v. on CRF-induced delayed gastric emptying (GE) was investigated in conscious rats. Gastric transit was assessed by the recovery of methyl cellulose/phenol red solution 20 min after its intragastric administration. The 55% inhibition of GE induced by CRF (0.6 µg i.v.) was antagonized by 87 and 100% by i.v. astressin at 3 and 10 µg, respectively, and by 68 and 64% by i.v. D-Phe CRF12-41 at 10 and 20 µg, respectively. CRF (0.6 µg)-injected intracisternally (i.c.) induced 68% reduction of GE was not modified by i.v. astressin (10 µg) whereas i.c. astressin (3 or 10 µg) blocked by 58 and 100%, respectively, i.v. CRF inhibitory action. Abdominal surgery with cecal manipulation reduced GE to 7.1 ± 3.1 and 27.5 ± 3.3% at 30 and 180 min postsurgery, respectively, compared with 40.3 ± 4.3 and 59.5 ± 2.9% at similar times after anesthesia alone. Astressin (3 µg i.v.) completely and D-Phe CRF12-41 (20 µg i.v.) partially (60%) blocked surgery-induced gastric stasis observed at 30 or 180 min. The CRF antagonists alone (i.v. or i.c.) had no effect on basal GE. These data indicate that CRF acts in the brain and periphery to inhibit GE through receptor-mediated interaction and that peripheral CRF is involved in acute postoperative gastric ileus; astressin is a potent peripheral antagonist of CRF when injected i.v. whereas i.c. doses >= 3 µg exert dual central and peripheral blockade of CRF action on gastric transit.

0022-3565/99/2902-0629$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. M. Gardiner, J. E. March, P. A. Kemp, A. P. Davenport, K. E. Wiley, and T. Bennett
Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 53 - 60.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C Beglinger and L Degen
Role of thyrotrophin releasing hormone and corticotrophin releasing factor in stress related alterations of gastrointestinal motor function
Gut, July 1, 2002; 51(90001): i45 - 49.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. Martinez, L. Wang, J. E. Rivier, W. Vale, and Y. Tache
Differential Actions of Peripheral Corticotropin-Releasing Factor (CRF), Urocortin II, and Urocortin III on Gastric Emptying and Colonic Transit in Mice: Role of CRF Receptor Subtypes 1 and 2
J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 611 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
L. Wang, V. Martinez, J. E. Rivier, and Y. Tache
Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1401 - R1410.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
N. Kihara, M. Fujimura, I. Yamamoto, E. Itoh, A. Inui, and M. Fujimiya
Effects of central and peripheral urocortin on fed and fasted gastroduodenal motor activity in conscious rats
Am J Physiol Gastrointest Liver Physiol, March 1, 2001; 280(3): G406 - G419.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Million, C. Maillot, P. Saunders, J. Rivier, W. Vale, and Y. Tache
Human urocortin II, a new CRF-related peptide, displays selective CRF2-mediated action on gastric transit in rats
Am J Physiol Gastrointest Liver Physiol, January 1, 2002; 282(1): G34 - G40.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.